Endogenex is developing the ReCET™ System, which utilizes controlled, non-thermal pulsed electric fields delivered endoscopically to reset metabolic signaling in the duodenum. This approach aims to restore metabolic function and improve blood glucose control for patients with type 2 diabetes.
Funding
$140.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 2 diabetes (T2D) affects over 400 million people globally, and a significant portion struggle to maintain adequate blood glucose control despite available treatments. Current therapies often focus on managing downstream effects rather than addressing the underlying metabolic dysfunction, potentially leading to disease progression and increased healthcare costs.
Solution
Endogenex is developing the ReCET™ System, an investigational device designed to reset metabolic signaling in the duodenum using controlled, non-thermal pulsed electric fields delivered endoscopically. The ReCET System aims to restore the natural signaling process of the duodenum, helping the body better control blood glucose levels and potentially slow the progression of type 2 diabetes. The technology is based on the principle of eliminating poorly functioning signaling cells in the duodenum to reset the metabolic operating system. The ReCET system is currently under evaluation in clinical studies in the United States and Australia.
Target Audience
The primary audience includes clinical providers, such as endocrinologists and gastroenterologists, interested in novel therapeutic approaches for managing type 2 diabetes, as well as patients with T2D seeking alternative treatment options.
Features
- Endoscopic delivery of controlled, non-thermal pulsed electric fields to the duodenum
- Designed to reset metabolic signaling and restore natural signaling processes
- Aims to improve blood glucose control and slow the progression of type 2 diabetes
- Utilizes a novel approach to eliminate poorly functioning signaling cells
- Investigational device under evaluation in pivotal clinical studies